Olympiad Research LP Takes $219,000 Position in Teleflex Incorporated (NYSE:TFX)

Olympiad Research LP acquired a new stake in shares of Teleflex Incorporated (NYSE:TFX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 1,231 shares of the medical technology company’s stock, valued at approximately $219,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of TFX. Janus Henderson Group PLC grew its stake in shares of Teleflex by 2.8% in the third quarter. Janus Henderson Group PLC now owns 5,376,452 shares of the medical technology company’s stock worth $1,329,704,000 after purchasing an additional 147,147 shares during the last quarter. State Street Corp grew its stake in shares of Teleflex by 1.0% in the third quarter. State Street Corp now owns 2,057,080 shares of the medical technology company’s stock worth $508,757,000 after purchasing an additional 21,291 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Teleflex by 0.5% in the third quarter. Geode Capital Management LLC now owns 1,130,560 shares of the medical technology company’s stock worth $278,676,000 after purchasing an additional 5,746 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Teleflex by 0.4% in the third quarter. Massachusetts Financial Services Co. MA now owns 427,579 shares of the medical technology company’s stock worth $105,749,000 after purchasing an additional 1,884 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its stake in shares of Teleflex by 31.2% in the third quarter. Point72 Asset Management L.P. now owns 407,442 shares of the medical technology company’s stock worth $100,768,000 after purchasing an additional 96,958 shares during the last quarter. 95.62% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts recently issued reports on TFX shares. StockNews.com raised Teleflex from a “hold” rating to a “buy” rating in a research note on Thursday, November 28th. Royal Bank of Canada lowered their price objective on shares of Teleflex from $275.00 to $245.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Needham & Company LLC restated a “hold” rating on shares of Teleflex in a report on Monday, December 16th. Truist Financial lowered their price objective on shares of Teleflex from $227.00 to $200.00 and set a “hold” rating for the company in a report on Wednesday, December 18th. Finally, Mizuho lowered their price objective on shares of Teleflex from $275.00 to $250.00 and set a “neutral” rating for the company in a report on Friday, November 1st. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $246.00.

Teleflex Price Performance

TFX stock opened at $175.43 on Monday. The firm has a 50 day moving average price of $176.98 and a 200-day moving average price of $207.23. Teleflex Incorporated has a 52-week low of $165.62 and a 52-week high of $249.90. The firm has a market capitalization of $8.15 billion, a price-to-earnings ratio of 34.88, a PEG ratio of 1.73 and a beta of 1.16. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.39 and a current ratio of 2.42.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.